Podcasts about bugworks

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/NAX865. CME/MOC/AAPA credit will be available until December 16, 2024.Shattering the Barriers to Glioblastoma Care: Revolutionary Advances With Innovative Technologies and Modern Systemic Approaches In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Brain Tumor Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Blue Earth Diagnostics and Novocure, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerSteven Brem, MD, has no financial interests/relationships or affiliations in relation to this activity.Faculty/PlannerManmeet S. Ahluwalia, MD, MBA, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AnHeart Therapeutics; Apollomics, Inc.; Autem Therapeutics; Bayer Corporation; Bugworks; Cairn Therapeutics; Caris Life Sciences; Celularity, Inc.; GSK; GT Medical Technologies; Insightec; Janssen Pharmaceuticals, Inc.; Kiyatec Inc.; Modifi Bio; NH TherAguix; Novocure, Inc.; Nuvation Bio, Inc.; Prelude Therapeutics; Pyramid Biosciences; Sumitomo Dainippon Pharma Oncology; The Menarini Group; Tocagen Inc.; Varian Medical Systems, Inc.; ViewRay Technologies, Inc.; Voyager Therapeutics, Inc.; and Xoft, a subsidiary of iCAD, Inc.Grant/Research Support from Seagen Inc.Stock Shareholder in CytoDyn Inc.; MedInnovate Advisors LLC; and MimiVax, LLC.Faculty/PlannerMichelle Kim, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Blue Earth Diagnostics.Patient/PlannerJB Bird has no financial interests/relationships or affiliations in relation to this activity.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/AWE865. CME credit will be available until December 27, 2024.Brainstorming New Approaches to Improve Glioblastoma Care: Revolutionary Advances With Modern Gene Fusion–Targeted Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerManmeet S. Ahluwalia, MD, MBA, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AnHeart Therapeutics; Apollomics, Inc.; Autem Therapeutics; Bayer Corporation; Bugworks; Cairn Therapeutics; Caris Life Sciences; Celularity, Inc.; GSK; GT Medical Technologies; Insightec; Janssen Pharmaceuticals, Inc.; Kiyatec Inc.; Modifi Bio; NH TherAguix; Novocure, Inc.; Nuvation Bio, Inc.; Prelude Therapeutics; Pyramid Biosciences; Sumitomo Dainippon Pharma Oncology; The Menarini Group; Tocagen Inc.; Varian Medical Systems, Inc.; ViewRay Technologies, Inc.; Voyager Therapeutics, Inc.; and Xoft, a subsidiary of iCAD, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/NAX865. CME/MOC/AAPA credit will be available until December 16, 2024.Shattering the Barriers to Glioblastoma Care: Revolutionary Advances With Innovative Technologies and Modern Systemic Approaches In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Brain Tumor Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Blue Earth Diagnostics and Novocure, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerSteven Brem, MD, has no financial interests/relationships or affiliations in relation to this activity.Faculty/PlannerManmeet S. Ahluwalia, MD, MBA, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AnHeart Therapeutics; Apollomics, Inc.; Autem Therapeutics; Bayer Corporation; Bugworks; Cairn Therapeutics; Caris Life Sciences; Celularity, Inc.; GSK; GT Medical Technologies; Insightec; Janssen Pharmaceuticals, Inc.; Kiyatec Inc.; Modifi Bio; NH TherAguix; Novocure, Inc.; Nuvation Bio, Inc.; Prelude Therapeutics; Pyramid Biosciences; Sumitomo Dainippon Pharma Oncology; The Menarini Group; Tocagen Inc.; Varian Medical Systems, Inc.; ViewRay Technologies, Inc.; Voyager Therapeutics, Inc.; and Xoft, a subsidiary of iCAD, Inc.Grant/Research Support from Seagen Inc.Stock Shareholder in CytoDyn Inc.; MedInnovate Advisors LLC; and MimiVax, LLC.Faculty/PlannerMichelle Kim, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Blue Earth Diagnostics.Patient/PlannerJB Bird has no financial interests/relationships or affiliations in relation to this activity.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/AWE865. CME credit will be available until December 27, 2024.Brainstorming New Approaches to Improve Glioblastoma Care: Revolutionary Advances With Modern Gene Fusion–Targeted Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerManmeet S. Ahluwalia, MD, MBA, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AnHeart Therapeutics; Apollomics, Inc.; Autem Therapeutics; Bayer Corporation; Bugworks; Cairn Therapeutics; Caris Life Sciences; Celularity, Inc.; GSK; GT Medical Technologies; Insightec; Janssen Pharmaceuticals, Inc.; Kiyatec Inc.; Modifi Bio; NH TherAguix; Novocure, Inc.; Nuvation Bio, Inc.; Prelude Therapeutics; Pyramid Biosciences; Sumitomo Dainippon Pharma Oncology; The Menarini Group; Tocagen Inc.; Varian Medical Systems, Inc.; ViewRay Technologies, Inc.; Voyager Therapeutics, Inc.; and Xoft, a subsidiary of iCAD, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/AWE865. CME credit will be available until December 27, 2024.Brainstorming New Approaches to Improve Glioblastoma Care: Revolutionary Advances With Modern Gene Fusion–Targeted Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerManmeet S. Ahluwalia, MD, MBA, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AnHeart Therapeutics; Apollomics, Inc.; Autem Therapeutics; Bayer Corporation; Bugworks; Cairn Therapeutics; Caris Life Sciences; Celularity, Inc.; GSK; GT Medical Technologies; Insightec; Janssen Pharmaceuticals, Inc.; Kiyatec Inc.; Modifi Bio; NH TherAguix; Novocure, Inc.; Nuvation Bio, Inc.; Prelude Therapeutics; Pyramid Biosciences; Sumitomo Dainippon Pharma Oncology; The Menarini Group; Tocagen Inc.; Varian Medical Systems, Inc.; ViewRay Technologies, Inc.; Voyager Therapeutics, Inc.; and Xoft, a subsidiary of iCAD, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/NAX865. CME/MOC/AAPA credit will be available until December 16, 2024.Shattering the Barriers to Glioblastoma Care: Revolutionary Advances With Innovative Technologies and Modern Systemic Approaches In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Brain Tumor Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Blue Earth Diagnostics and Novocure, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerSteven Brem, MD, has no financial interests/relationships or affiliations in relation to this activity.Faculty/PlannerManmeet S. Ahluwalia, MD, MBA, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AnHeart Therapeutics; Apollomics, Inc.; Autem Therapeutics; Bayer Corporation; Bugworks; Cairn Therapeutics; Caris Life Sciences; Celularity, Inc.; GSK; GT Medical Technologies; Insightec; Janssen Pharmaceuticals, Inc.; Kiyatec Inc.; Modifi Bio; NH TherAguix; Novocure, Inc.; Nuvation Bio, Inc.; Prelude Therapeutics; Pyramid Biosciences; Sumitomo Dainippon Pharma Oncology; The Menarini Group; Tocagen Inc.; Varian Medical Systems, Inc.; ViewRay Technologies, Inc.; Voyager Therapeutics, Inc.; and Xoft, a subsidiary of iCAD, Inc.Grant/Research Support from Seagen Inc.Stock Shareholder in CytoDyn Inc.; MedInnovate Advisors LLC; and MimiVax, LLC.Faculty/PlannerMichelle Kim, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Blue Earth Diagnostics.Patient/PlannerJB Bird has no financial interests/relationships or affiliations in relation to this activity.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/AWE865. CME credit will be available until December 27, 2024.Brainstorming New Approaches to Improve Glioblastoma Care: Revolutionary Advances With Modern Gene Fusion–Targeted Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerManmeet S. Ahluwalia, MD, MBA, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AnHeart Therapeutics; Apollomics, Inc.; Autem Therapeutics; Bayer Corporation; Bugworks; Cairn Therapeutics; Caris Life Sciences; Celularity, Inc.; GSK; GT Medical Technologies; Insightec; Janssen Pharmaceuticals, Inc.; Kiyatec Inc.; Modifi Bio; NH TherAguix; Novocure, Inc.; Nuvation Bio, Inc.; Prelude Therapeutics; Pyramid Biosciences; Sumitomo Dainippon Pharma Oncology; The Menarini Group; Tocagen Inc.; Varian Medical Systems, Inc.; ViewRay Technologies, Inc.; Voyager Therapeutics, Inc.; and Xoft, a subsidiary of iCAD, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/NAX865. CME/MOC/AAPA credit will be available until December 16, 2024.Shattering the Barriers to Glioblastoma Care: Revolutionary Advances With Innovative Technologies and Modern Systemic Approaches In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Brain Tumor Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Blue Earth Diagnostics and Novocure, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerSteven Brem, MD, has no financial interests/relationships or affiliations in relation to this activity.Faculty/PlannerManmeet S. Ahluwalia, MD, MBA, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AnHeart Therapeutics; Apollomics, Inc.; Autem Therapeutics; Bayer Corporation; Bugworks; Cairn Therapeutics; Caris Life Sciences; Celularity, Inc.; GSK; GT Medical Technologies; Insightec; Janssen Pharmaceuticals, Inc.; Kiyatec Inc.; Modifi Bio; NH TherAguix; Novocure, Inc.; Nuvation Bio, Inc.; Prelude Therapeutics; Pyramid Biosciences; Sumitomo Dainippon Pharma Oncology; The Menarini Group; Tocagen Inc.; Varian Medical Systems, Inc.; ViewRay Technologies, Inc.; Voyager Therapeutics, Inc.; and Xoft, a subsidiary of iCAD, Inc.Grant/Research Support from Seagen Inc.Stock Shareholder in CytoDyn Inc.; MedInnovate Advisors LLC; and MimiVax, LLC.Faculty/PlannerMichelle Kim, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Blue Earth Diagnostics.Patient/PlannerJB Bird has no financial interests/relationships or affiliations in relation to this activity.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/NAX865. CME/MOC/AAPA credit will be available until December 16, 2024.Shattering the Barriers to Glioblastoma Care: Revolutionary Advances With Innovative Technologies and Modern Systemic Approaches In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Brain Tumor Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Blue Earth Diagnostics and Novocure, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerSteven Brem, MD, has no financial interests/relationships or affiliations in relation to this activity.Faculty/PlannerManmeet S. Ahluwalia, MD, MBA, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AnHeart Therapeutics; Apollomics, Inc.; Autem Therapeutics; Bayer Corporation; Bugworks; Cairn Therapeutics; Caris Life Sciences; Celularity, Inc.; GSK; GT Medical Technologies; Insightec; Janssen Pharmaceuticals, Inc.; Kiyatec Inc.; Modifi Bio; NH TherAguix; Novocure, Inc.; Nuvation Bio, Inc.; Prelude Therapeutics; Pyramid Biosciences; Sumitomo Dainippon Pharma Oncology; The Menarini Group; Tocagen Inc.; Varian Medical Systems, Inc.; ViewRay Technologies, Inc.; Voyager Therapeutics, Inc.; and Xoft, a subsidiary of iCAD, Inc.Grant/Research Support from Seagen Inc.Stock Shareholder in CytoDyn Inc.; MedInnovate Advisors LLC; and MimiVax, LLC.Faculty/PlannerMichelle Kim, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Blue Earth Diagnostics.Patient/PlannerJB Bird has no financial interests/relationships or affiliations in relation to this activity.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/NAX865. CME/MOC/AAPA credit will be available until December 16, 2024.Shattering the Barriers to Glioblastoma Care: Revolutionary Advances With Innovative Technologies and Modern Systemic Approaches In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Brain Tumor Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Blue Earth Diagnostics and Novocure, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerSteven Brem, MD, has no financial interests/relationships or affiliations in relation to this activity.Faculty/PlannerManmeet S. Ahluwalia, MD, MBA, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AnHeart Therapeutics; Apollomics, Inc.; Autem Therapeutics; Bayer Corporation; Bugworks; Cairn Therapeutics; Caris Life Sciences; Celularity, Inc.; GSK; GT Medical Technologies; Insightec; Janssen Pharmaceuticals, Inc.; Kiyatec Inc.; Modifi Bio; NH TherAguix; Novocure, Inc.; Nuvation Bio, Inc.; Prelude Therapeutics; Pyramid Biosciences; Sumitomo Dainippon Pharma Oncology; The Menarini Group; Tocagen Inc.; Varian Medical Systems, Inc.; ViewRay Technologies, Inc.; Voyager Therapeutics, Inc.; and Xoft, a subsidiary of iCAD, Inc.Grant/Research Support from Seagen Inc.Stock Shareholder in CytoDyn Inc.; MedInnovate Advisors LLC; and MimiVax, LLC.Faculty/PlannerMichelle Kim, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Blue Earth Diagnostics.Patient/PlannerJB Bird has no financial interests/relationships or affiliations in relation to this activity.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/AWE865. CME credit will be available until December 27, 2024.Brainstorming New Approaches to Improve Glioblastoma Care: Revolutionary Advances With Modern Gene Fusion–Targeted Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerManmeet S. Ahluwalia, MD, MBA, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AnHeart Therapeutics; Apollomics, Inc.; Autem Therapeutics; Bayer Corporation; Bugworks; Cairn Therapeutics; Caris Life Sciences; Celularity, Inc.; GSK; GT Medical Technologies; Insightec; Janssen Pharmaceuticals, Inc.; Kiyatec Inc.; Modifi Bio; NH TherAguix; Novocure, Inc.; Nuvation Bio, Inc.; Prelude Therapeutics; Pyramid Biosciences; Sumitomo Dainippon Pharma Oncology; The Menarini Group; Tocagen Inc.; Varian Medical Systems, Inc.; ViewRay Technologies, Inc.; Voyager Therapeutics, Inc.; and Xoft, a subsidiary of iCAD, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/AWE865. CME credit will be available until December 27, 2024.Brainstorming New Approaches to Improve Glioblastoma Care: Revolutionary Advances With Modern Gene Fusion–Targeted Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerManmeet S. Ahluwalia, MD, MBA, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AnHeart Therapeutics; Apollomics, Inc.; Autem Therapeutics; Bayer Corporation; Bugworks; Cairn Therapeutics; Caris Life Sciences; Celularity, Inc.; GSK; GT Medical Technologies; Insightec; Janssen Pharmaceuticals, Inc.; Kiyatec Inc.; Modifi Bio; NH TherAguix; Novocure, Inc.; Nuvation Bio, Inc.; Prelude Therapeutics; Pyramid Biosciences; Sumitomo Dainippon Pharma Oncology; The Menarini Group; Tocagen Inc.; Varian Medical Systems, Inc.; ViewRay Technologies, Inc.; Voyager Therapeutics, Inc.; and Xoft, a subsidiary of iCAD, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

It's World Antimicrobial Awareness Week and this year's theme is “Preventing Antimicrobial Resistance Together”. We chat to Bugworks, a clinical stage pharmaceutical company, headquartered in the US, with subsidiaries in India and Australia, currently developing novel antibacterials and immunotherapies.Bugworks' Co-founder and Chief Executive Officer, Dr Anand Anandkumar, joins the podcast from Bangalore, India to talk about the challenges of developing new antimicrobials, the boost from CARB-X accelerator that is keeping their lights on, and why push and pull incentives are vital for innovation. Dr Anandkumar reveals why the company chose Adelaide in South Australia as the site for the first-in-human Phase 1 clinical trial of one of two antibacterial agents in development. And we pose the question – does Australia need a CARB-X style accelerator to supercharge its efforts to curb AMR?Joining host Caroline Duell is Andrew Bowskill, MTPConnect's Director of Stakeholder Engagement for Queensland and co-chair of the Australian Antimicrobial Resistance Network (AAMRNet), established by MTPConnect as Australia's first multi-stakeholder expert group formed to address the impact of antimicrobial resistance (AMR) on human health. AAMRNet, in conjunction with CSIRO, recently released the ‘Antimicrobial Resistance (AMR) Impact Report: How big is Australia's AMR threat?, which reviews gaps in our data collection methods to find out how many people are dying from drug-resistant infections in Australia. 

Two centuries ago, people could die from a simple scratch. It was the pre-antibiotic era when infections killed babies within hours, a cold could turn deadly within days, and people survived injuries through luck alone.Now a pill can prevent strep throat from turning into scarlet fever and antibiotics keep surgery safe. But because bacteria evolve and mutate so quickly, many drugs are powerless against new strains. The world needs new and better antibiotics.In this episode of One World, One Health, Anand Anandkumar, co-founder and chief executive officer of Bugworks, explains what his company is doing to help discover and develop new antibiotics. Antibiotics are not big money makers for pharmaceutical companies, so Bugworks is putting together funding from governments, charities, and a new kind of motivated investor.Listen as Anand Anandkumar tells host Maggie Fox about what his company is trying to do.

In this edition of Founder Thesis, Akshay Datt talks with Dr. Anand Anandkumar, CEO and MD of Bugworks Research Inc., a remarkable drug discovery company focused on developing novel broad-spectrum antibiotics and immunotherapies that stand to transform the healthcare ecosystem worldwide. A veteran in the semiconductor industry with almost two decades of experience, Dr. Anandkumar wears many hats. To mention a few, he is the Vice President of the India Biotech Association & one of the founding members of the India Electronics and Semiconductor Association (IESA). In 2005, he founded Cellworks which has significantly increased the success rate of cancer treatments by customizing therapy choices. An offshoot of Cellworks, Bugworks originated from the deep resolve to eradicate secondary bacterial infections, a major public health threat in terms of mortality. Tune in to this episode to hear Dr. Anandkumar speak about how Bugworks has taken a unique path in drug discovery as it attempts to fight the war against rising antibacterial resistance. What you must not miss! Current drug development challenges Monetizing drug combination therapies AMR and superbugs ----- If you want to be a podcaster, then check out Zencastr.com which is also the generous sponsor for this episode. Zencastr is like a Shopify for podcasters taking care of all your needs from recording to editing to hosting.  Show your love for this show by using this link to sign up: https://zen.ai/founderthesis (https://zen.ai/founderthesis)

Show notes: In this episode, we imagine a post-antibiotic future for India - where bacteria have learned to fight our entire arsenal of antibiotics. This future is rather dystopian, but don't worry, we have experts who will tell us how we can avoid getting to this future. We hear of solutions for the social problems we need to crack, and we have an expert whose small company in Bangalore is developing a whole new class of antibiotics. Bonus episode coming soon! Imagined Tomorrow is created and hosted by Shreya Dasgupta. The episode was co-edited by Abhishek Madan. Intro and outro music is by Abhijit Shylanath. Get in touch via Twitter, or email imagined.tomorrow@gmail.com. Guests: Subject experts Dr. Jyoti Joshi, a medical doctor and the South Asia head of the Center For Disease Dynamics, Economics & Policy or CDDEP. Dr. Prashanth N. Srinivas, a medical doctor and public health researcher at the Institute of Public Health, Bangalore. Dr. Anand Anandkumar, CEO and MD of Bugworks, a Bangalore-based company that is developing a new class of antibiotics. Others Dumma (Maya Sengupta): My incredibly talented maternal grandmother, who tells me stories of her childhood, when she hadn't even heard of antibiotics. Episode music Interlude music pieces by Alfred Castro, Oleksii Kaplunskyi, Zakar Walaha on Pixabay. Episode artwork Image of a carbapenem-resistant Klebsiella pneumoniae by NIAID, used under CC By 2.0 license. For further reading: Scoping Report on Antimicrobial Resistance in India. Read here. More on Bugworks' research Explainer: Why Is Multi-Drug Resistance a Problem? Read here. Thumbs-up to pneumococcal vaccine rollout across India. Read here. Too much too often: Antibiotics in Indian crops can make them ineffective. Read here.

In this Episode, I (@Jivraj Singh Sachar) speak with Anand Anandkumar, the Founder and CEO of Bugworks, a drug discovery company trying to find a solution for the super bugs! Anand is such an articulate, passionate and thoughtful founder. It was a treat to speak with him and unbundle years of his diverse experiences on the Episode. From his days of completing his PhD, working in the chip industry, starting Cellworks and eventually targeting the unsolvable problem of fighting Super Bugs with Bugworks. Anand is an incredible founder and innovator, leading the innovation in Biotechnology and health-technology from India. Through the Episode we discuss the following: 1. (3:45) - Wealth as a Motivation in Starting Up 2. (6:44) - Navigating through Anand's journey - a result of a series of Decisions 3. (15:25) - The Paradox of Privilege 4. (22:49) - Understanding BioTech & HealthTech in India 5. (30:56) - Making Great People believe in his Vision to solve an Unsolvable Problem 6. (37:53) - Patience & Perseverance as Founder || Chief Ecosystem Officer! 7. (46:44) - Lessons for Leadership from 25 years of Experience || DEN - Dreamer, Executioner, Networker 8. (52:56) - Anand's Belief System 9. (59:40) - One Final Thought || Understanding the Opportunity 10. (61:23) - Summary That was it from the 32nd Episode of the Indian Silicon Valley Podcast - Understanding the Opportunity. We're available on Instagram & Twitter. Feel free to drop in your feedback! Subscribe to our WhatsApp Newsletter! I, Jivraj, am reachable on LinkedIn & Twitter! "If you never try, you never know" Stay Tuned, Keep Building.

In this episode, Dr. Anand Anandkumar, Founder & CEO @Bugworks, joins our host Digjay, to talk about his experience of working in different domains across multiple geographies, what led him to become an entrepreneur in his late 40s and his pursuit of solving problems at scale, fund raising challenges for deep science startups & how should founders navigate these challenges. Listed in the top 36 global gamechanging startups to watch out for in 2019 by CB Insights, Bugworks Research is a deep science startup that aims to discover novel treatment options for resistant bacterial infections. The company has won many national/international innovation awards and is the 1st company outside North America and Europe to win the coveted CARB-X grant. Prior to Bugworks, Dr. Anand was the co-founder and CEO of Cellworks, a company specialising in personalized oncotherapy by making use of mathematical modelling frameworks, the co-founding Managing Director of the India operation of SpinCircuit (acq by Cadence, 2003) and Magma Design Automation (acq by Synopsys, 2011). He is also the co-founder of EVA, a life sciences and healthcare accelerator and founding member of TiE Bangalore. You can connect with him here on Linkedin / Twitter ---- If you liked our episode, you can subscribe to our podcast on any of the major podcasting platforms like Spotify, Apple iTunes and Google Podcasts. Please leave us a review on Apple iTunes to help others discover this podcast. You can visit thevcpreneur.com and follow us on Twitter @thevcpreneur_ & Instagram @thevcpreneur for more episodes and interesting insights on the startup ecosystem. You can also follow our host Digjay on Linkedin & Twitter ---- Show notes: 1. (01:16) Dr. Anand's background in semiconductor and biotech space & path leading up to Bugworks 2. (09:06) Key stakeholders in driving R&D and funding in deep sciences; Factors constraining VCs from allocating more capital in this space 3. (14:20) Lessons from the fund raising experience at Bugworks; Importance of tapping global investors & seeking non-dilutive funding options like government grants 4. (19:06) What do VCs bet on when they invest in healthcare/bio-tech startups? Treating investors as part of your extended team and taking the onus of making them subject matter experts 5. (24:10) Need for more mentors in this space and the role of specialized accelerators/incubators 6. (32:00) Characteristics of a strong founding team 7. (33:55) Rapid fire and closing remarks

In today's episode, Pranav Pai, Founding Partner @3one4 Capital joins our host Digjay, to share about his journey leading into venture capital, how 3one4 Capital differentiates itself from other VC funds, challenges of founding and managing a venture capital fund, the key metrics used at 3one4 Capital to measure it's performance as a VC fund and preparing their portfolio companies for a crisis. Pranav is a Founding Partner at 3one4 Capital - an early-stage venture capital fund based in Bangalore, India. The fund manages a corpus of ~INR 800 Cr (+$110MM) with a portfolio of 50+ early-stage investments across various technology, product, and platform companies in India and US. Pranav has been awarded the “35 under 35” Entrepreneurs of India for 2017 and the “40 under 40” Alternative Investments Professionals of India for 2020. Some of his investments include Licious, Betterplace, Open, Jupiter, ToneTag, DarwinBox, Faircent, Bugworks, Pocket Aces, YourStory, and Tracxn. Pranav is a Stanford Alum, and is the co-president of Stanford Angels & Entrepreneurs India. You can connect with him here on Linkedin / Twitter If you liked our episode, you can subscribe to our podcast on any of the major podcasting platforms like Spotify, Apple iTunes and Google Podcasts. Please leave us a review on Apple iTunes and help others discover this podcast. You can visit thevcpreneur.com and follow us on Twitter @thevcpreneur_ & Instagram @thevcpreneur for more episodes and interesting insights on the startup ecosystem. You can also follow our host Digjay here on Linkedin / Twitter Show notes – 1. Pranav's background and path to Venture Capital (VC) 2. How is 3one4 Capital different from traditional VC funds? 3. Attracting the best startups; Startup evaluation process at 3one4 Capital 4. Learnings from his time at Stanford and working in the Bay Area 5. Challenges of launching a Venture Capital fund 6. How does 3one4 Capital assess its own performance as a VC fund? What are the qualitative aspects that they focus on? 7. How to prepare yourself and your portfolio companies for a crisis; Surviving the pandemic 8. Rapid fire questions and closing remarks

Bugworks Research, Inc., is a company focused on producing a next generation antibiotic in light of antibiotic resistance. Dr. Datta details surrounding issues, including Why there have been no new antibiotics introduced in the last 50 years, How this new broad spectrum antibiotic is designed to evade antibiotic resistance, and  Which bacteria in particular it targets and under what circumstances. Dr. Santanu Datta is the CSO of Bugworks, Inc., and has been working in the field of infectious disease for decades. He begins telling listeners about the background of antibiotic development, highlighting the difference it has made. He explains why it has been difficult to develop new antibiotics from both a market and scientific perspective. He also explains the mechanisms of antibiotic and bacteria interaction, from the parts the antibiotics have traditionally targeted to the types of adaptations and evolutions bacteria are able to make to impede antibiotics, resulting in antibiotic resistance. He then talks about his company's work to make a new broad spectrum antibiotic that targets the most dangerous bacteria hospitals face in one antibiotic, from E. coli to Staphylococcus aureus to other common bacteria in hospital patients. Therefore, doctors may use this in an IV form when they don't have time to wait for test results because of the health risks to the patient. Dr. Datta explains that his new generation antibiotic targets two parts of the bacteria at once, limiting its ability to escape unharmed. One of the targets includes the enzyme bacteria require for replication. He also explains their approval process as they head towards phase 1 and adds that they are funded by Carb-x. For more, see the company's web site at https://bugworksresearch.com/

I had an amazing conversation with Anand AnandKumar, who is the CEO & Co-Founder of Bugworks. Bugwork's mission is to bring innovation into Antibiotics (which hasn't seen any in 60 years) and to stop the spread of Global Superbugs. A superbug is any disease that can't be treated through existing antibiotics. The importance of Anand's work is magnified given the current spread of the coronavirus. Anand is driven by a passion to solve one of the greatest challenges that face our planet today and a deep purpose that was brought from 2 near death experiences. Some of the key takeaways I took from the podcast were: Passion and meaning will drive you toward waking up everyday to solving such an enormous problem. Getting drugs to market, especially for small companies, only have a 5% success rate and take 10 years. You need passion to get through thatThis will also help push through rejection. To get funding for Bugworks, Anand pitched to over 200 people to get enough funding for Bugworks and the same was for Cellworks The People you surround yourself with are so important - Good people are the difference between successful and unsuccessful teams. It's never too late to pivot - Anand was in very deep into his career before switching to the Bio-Medical field from semi conductors. If you're looking to solve an enormous problem and don't know how to start, this episode is for you as Anand dives deep into the challenges he's faced and how he has got through them.